Long-term tumor regressions have been observed in patients following the adoptive transfer
of autologous tumor-infiltrating lymphocytes or genetically modified T cells expressing MHC
class I-restricted T-cell receptors (TCRs), but clinical trials have not evaluated responses to
genetically modified T cells expressing antitumor MHC class II-restricted TCRs. As studies
carried out in a murine tumor model system have demonstrated that the adoptive transfer of
CD4+ T cells could lead to the regression of established tumors, we plan to test the …